ABSTRACT: Human skin fibroblast cell line, Susa was treated with DMSO (control) or with fraglide-1 (5H4PB) for 24h subjected to RNA extraction for RNA-seq.
Project description:MDA-PCa2b cells were treated with PCT-209 or control (DMSO) for 24h and subjected to the qRT-PCR based microarray analysis (Qiagen, Germantown, MD).
Project description:In order to examine the effects of sudemycin D1 on the whole transcriptome, we exposed Rh18 cells to 1μM of drug for 8hr and after extraction, subjected RNA to RNAseq analysis. Control samples were treated with the vehicle (DMSO) alone and all analyses were conducted in triplicate.
Project description:To investigate the effect of HDAC inhibition, we treated MKL1 cells with 10µM of domatinostat or vehicle control (DMSO) for 24h, and carried out bulk RNA-seq We then performed gene expression profiling analysis using data obtained from RNA-seq of vehicle control (DMSO treated) and domatinostat treated samples (in duplicates)
Project description:The NPC cell line C666_1 is known to be infected with Epstein Barr virus (EBV), and to have high expression of SSTR2A. The cell line was treated with PENN221 (an SSTR2A targeted drug conjugate) , Belinostat (a histone deacetylase inhibitor), DMSO (negative control) or left untreated (negative control). Both PENN221 and Belinstat resulted in increased cell death of the cell line. Treated samples were sequenced at 24h and 72h post treatment.
Project description:Investigation of the time dependent effect of Cpd1 (small molecule interactor) on the proteome composition of melanoma WM3734 line by label-free quantification using mass spectrometry. The goal was to identify which protein abundances are increased upon treatment with Cpd1. Melanoma cell line WM3734 was treated with Cpd1 and with the control DMSO. Samples were taken at two time points, 24h and 72h.
Project description:Data independent acquisition (DIA) mass spectrometry was used to study the potent inhibitors for cancer derived fibroblast cell line, CT5-3hTERT. The fibroblast spheroids were treated with 21 different tumor inhibitors to compare their effect in proteome in comparison to treated with DMSO.
Project description:Dermal fibroblasts that were cultured from skin biopsy samples were treated for three days with either 1µM of erlotinib, 1µM of DMSO (vehicle), or no treatment. The cells were harvested on the fourth day for total RNA extraction and hybridization on Affymetrix Human GeneChip 133 Plus 2.0 microarrays.
